Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Dec 2024
Higher response rate, PFS, OS with cilta-cel, but ide-cel had lower rate of severe toxicity
Read Full NewsQurAlis reported interim ANQUR trial results showing target engagement, a biomarker signal, and a trend toward slower functional decline with QRL-201 in ALS.
Servier reported that sevasemten did not meet its primary or secondary endpoints in the pivotal GRAND CANYON trial for Becker muscular dystrophy.
GLP-1 RAs Linked to Lower Diabetes, CV Risk than Metformin in Prediabetes
1.
Top Options Are Discovered Through Direct Comparison of 25 Migraine Drugs.
2.
Dementia-like protein buildup found in pancreas cells before cancer develops
3.
Radiotherapy after mastectomy can be avoided, study finds
4.
Admissions, medical colleges, fees, and eligibility requirements information for the DNB Post Diploma in Radiation Oncology.
5.
WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research
1.
Quality of Life Through Identity Reconstruction and Social Reintegration After Cancer Treatment
2.
Essential Updates in Hematology in Daily Practice
3.
Exploring the Latest Advances in PTLD Cancer Treatment
4.
Radiopharmaceutical Theranostics: Precision Radiation Delivered Through Molecular Targeting
5.
Clonal Hematopoiesis and Healthy Aging: Clinical Implications, Mechanisms, and Emerging Perspectives
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
2.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
3.
Efficient Management of First line ALK-rearranged NSCLC - Part V
4.
Understanding Iron Deficiency and Its Common Symptoms
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge